Document Detail


The effect of montelukast on bronchial provocation tests and exhaled nitric oxide levels in asthmatic patients.
MedLine Citation:
PMID:  14650101     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Leukotriene antagonist therapy in asthmatic patients alleviates symptoms and improves exercise tolerance, however the effect of these drugs on bronchial provocation tests and exhaled nitric oxide levels are less clearly established. OBJECTIVE: To determine the effect of montelukast treatment on airway hyperresponsiveness to exercise, methacholine and adenosine-5'-monophosphate and on exhaled nitric oxide levels in steroid-naive asthmatics. METHODS: Following a 2 week run-in period, 20 mild to moderate asthmatics were enrolled in an open label 6 week trial of oral montelukast-sodium therapy. Bronchial hyperreactivity (exercise, methacholine and adenosine-5'-monophosphate challenges) and exhaled nitric oxide levels were measured before and after the 6 week period. RESULTS: Montelukast treatment resulted in a significant improvement in exercise tolerance: median delta FEV1 20.0% (range 0-50) prior to treatment vs. 15.0% (range 0-50) post-treatment (P = 0.029). A significant difference was also observed for exhaled NO following therapy: median NO 16.0 ppb (range 7-41) vs. 13.0 (range 4.8-26) (P = 0.016). No change was seen in baseline lung function tests (FEV1, MEF50) or in the bronchial responsiveness (PC20) for methacholine and adenosine-5'-monophosphate. CONCLUSIONS: This study demonstrates that the leukotriene antagonist montelukast-sodium reduces bronchial hyperreactivity in response to exercise and reduces exhaled nitric oxide levels but has little effect on bronchial responsiveness to methacholine and adenosine challenges.
Authors:
Neville Berkman; Avraham Avital; Elat Bardach; Chaim Springer; Raphael Breuer; Simon Godfrey
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The Israel Medical Association journal : IMAJ     Volume:  5     ISSN:  1565-1088     ISO Abbreviation:  Isr. Med. Assoc. J.     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-12-02     Completed Date:  2004-01-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  100930740     Medline TA:  Isr Med Assoc J     Country:  Israel    
Other Details:
Languages:  eng     Pagination:  778-81     Citation Subset:  IM    
Affiliation:
Institute of Pulmonology, Hadassah University Hospital, Hebrew University-Hadassah Medical School, Jerusalem, Israel. neville@hadassah.org.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetates / administration & dosage*
Adenosine / diagnostic use
Administration, Oral
Adolescent
Adult
Anti-Asthmatic Agents / administration & dosage*
Asthma / diagnosis,  drug therapy*,  metabolism
Bronchial Provocation Tests*
Bronchoconstrictor Agents / diagnostic use
Child
Exercise
Female
Humans
Male
Methacholine Chloride / diagnostic use
Middle Aged
Nitric Oxide / metabolism*
Quinolines / administration & dosage*
Spirometry
Treatment Outcome
Vasodilator Agents / diagnostic use
Chemical
Reg. No./Substance:
0/Acetates; 0/Anti-Asthmatic Agents; 0/Bronchoconstrictor Agents; 0/Quinolines; 0/Vasodilator Agents; 10102-43-9/Nitric Oxide; 158966-92-8/montelukast; 58-61-7/Adenosine; 62-51-1/Methacholine Chloride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quick parathormone assay in the surgical management of hyperparathyroidism.
Next Document:  The "DRIL" procedure--a neglected way to treat the "steal" syndrome of the hemodialysed patient.